Logotipo del repositorio
Logotipo del repositorio
 

Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?

Vista sencilla de ítem
dc.contributor.authorRojas, Joselyn
dc.contributor.authorOlivar, Luis Carlos
dc.contributor.authorChávez Castillo, Mervin
dc.contributor.authorMartínez, María Sofia
dc.contributor.authorWilches-Durán, Sandra
dc.date.accessioned2018-03-12T16:23:30Z
dc.date.available2018-03-12T16:23:30Z
dc.date.issued2017
dc.description.abstractEl Hiperparatiroidismo primario (HPTP) es un trastorno endocrino frecuente caracterizado por una secreción autónoma de hormona paratiroidea (PTH). Si bien, su variante asintomática es la más frecuentemente encontrada en la práctica clínica (la cual se diagnostica incidentalmente), las complicaciones óseas y renales afectan de forma importante la calidad de vida del paciente. Sin embargo, el espectro de manifestaciones de este trastorno no se limita al metabolismo mineral, puesto que las concentraciones elevadas de PTH se asocian a un mayor riesgo de alteraciones metabólicas como el síndrome metabólico, diabetes mellitus 2 y enfermedades cardiovasculares. En este ámbito, la hipertensión arterial (HTA), relacionada con aproximadamente 9,4 millones de muerte al año, ha sido considerada una manifestación no clásica del HPTP. La interacción PTH-Aldosterona ha surgido como un importante eslabón para tratar de explicar esta relación, planteándose diversos mecanismos teóricos que posicionan a la PTH como estimulador directo de la síntesis de aldosterona en las células de la zona glomerular. Sin embargo, estos mecanismos teóricos han estado rodeados de controversia en su aspecto epidemiológico y clínico, existiendo aún muy pocos estudios poblacionales explorando este vínculo y su relación con la morbimortalidad cardiovascular, por lo que es necesario mayor investigación en el área con el fin de conocer el verdadero impacto de estos mecanismos en la salud de los individuos. Esta revisión resume aspectos del metabolismo del calcio, al igual que los principales mecanismos subyacentes al vínculo HPTP-HTA, y los datos epidemiológicos disponibles sobre el tópico, a fin de brindar un mejor entendimiento sobre este novel planteamiento.spa
dc.description.abstractPrimary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by autonomic parathyroid hormone secretion (PTH). Although its asymptomatic variant is the most frequently found in clinical practice (which is incidentally diagnosed), bone and kidney complications significantly affect the patient’s quality of life. However, the spectrum of manifestations of this disorder is not limited to mineral metabolism, since elevated concentrations of PTH are associated with an increased risk of metabolic syndrome, type 2 diabetes mellitus and cardiovascular disease. In this area, hypertension (AHT), related to approximately 9.4 million deaths per year, has been considered a non-classical manifestation of PHPT. The interaction PTH-Aldosterone has emerged as an important link to try to explain this relationship, posing various theoretical mechanisms that position PTH as a direct stimulator of aldosterone synthesis in the glomerular zone cells. However, these theoretical mechanisms have been surrounded by controversy in their epidemiological and clinical aspects, and there are still very few population studies exploring this link and its relation with cardiovascular morbimortality, which is why more research is needed in the area in order to know. The true impact of these mechanisms on the health of individuals. This review summarizes aspects of calcium metabolism, as well as the main mechanisms underlying the HPTP-HTA link, and available epidemiological data on the topic, in order to provide a better understanding of this novel approach.eng
dc.identifier.issn18564550
dc.identifier.urihttp://hdl.handle.net/20.500.12442/1850
dc.language.isospaspa
dc.publisherCooperativa servicios y suministros 212518 RSspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.licenseLicencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacionalspa
dc.sourceRevista Latinoamericana de Hipertensiónspa
dc.sourceVol. 12, No.1 (2017)spa
dc.source.urihttps://www.redalyc.org/articulo.oa?id=170250838001
dc.subjectHiperparatirodismo primariospa
dc.subjectAldosteronaspa
dc.subjectHormona paratiroideaspa
dc.subjectHipertensión arterialspa
dc.subjectRiesgo cardiovascularspa
dc.subjectMortalidad cardiovascularspa
dc.subjectPrimary Hiperparathyroidismeng
dc.subjectAldosteroneeng
dc.subjectParathyroid hormoneeng
dc.subjectHypertensioneng
dc.subjectCardiovascular riskeng
dc.subjectCardiovascular mortalityeng
dc.titleHormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?spa
dc.typearticlespa
dcterms.referencesWHO. The top ten causes of death. Fact sheet No 310 / May 2014 Avalaible at: http://www. who.int/mediacentre/factsheets/fs310/en/.eng
dcterms.referencesWho. Global status report on noncommunicable diseases 2014. Available at: http://apps.who. int/iris/bitstream/10665/148114/1/9789241564854_eng.pdfeng
dcterms.referencesLim SS, Vos T, Flaxman AD, Danaei G, et al A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010 : a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380 (9859): 2224-60.eng
dcterms.referencesVelasco A, Vongpatanasin W. The evaluation and treatment of endocrine forms of hypertension. Curr Cardiol Rep. 2014;16(9):528.eng
dcterms.referencesRichert L, Trombetti A, Herrmann FR, Triponez F, Meier C, Robert JH, Rizzoli R. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swiss Med Wkly. 2009;139(27-28):400-4.eng
dcterms.referencesCordellat IM. Hiperparatiroidismo: ¿primario o secundario?. Reumatol Clin. 2012;8(5):287– 291eng
dcterms.referencesLafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res. 1991t;6 Suppl 2:S51-9; discussion S61.eng
dcterms.referencesMakras P, Papapoulos SE. Medical treatment of hypercalcaemia. Hormones (Athens). 2009;8(2):83-95.eng
dcterms.referencesWermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, Melton LJ 3rd. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21(1):171-7.eng
dcterms.referencesMelton LJ 3rd. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17 Suppl 2:N12-7.eng
dcterms.referencesBilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99(10):3561-9.eng
dcterms.referencesOrlov SN, Aksentsev SL, Kotelevtsev SV. Extracellular calcium is required for the maintenance of plasma membrane integrity in nucleated cells. Cell Calcium. 2005 Jul;38(1):53-7.eng
dcterms.referencesOzkul Y. Influence of calcium channel blocker drugs in neuromuscular transmission. Clin Neurophysiol. 2007;118(9):2005-8.eng
dcterms.referencesButenas S, Mann KG. Blood coagulation. Biochemistry (Mosc). 2002;67(1):3-12eng
dcterms.referencesBerridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29.eng
dcterms.referencesWang L, Nancollas GH, Henneman ZJ: Nanosized particles in bone and dissolution insensitivity of bone mineral. Biointerphases 1: 106 –111, 2006.eng
dcterms.referencesBaker SB, Worthley LI. The essentials of calcium, magnesium and phosphate metabolism: part I. Physiology. Crit Care Resusc. 2002;4(4):301-6.eng
dcterms.referencesPeacock M. Calcium Metabolism in Health and Disease. Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S23-30.eng
dcterms.referencesGoswami R, Mohapatra T, Gupta N, Rani R, Tomar N, Dikshit A, Sharma RK. P arathyroid hormone gene polymorphism and sporadic idiopathic hypoparathyroidism. J Clin Endocrinol Metab. 2004;89(10):4840-5.eng
dcterms.referencesJüppner, H, Gardella, TJ, Brown, EM, et al: Parathyroid hormone, and parathyroid hormonerelated peptide in the regulation of calcium homeostasis and bone development (chapt 70), in Endocrinology (2001, vol 2, 4th ed) edited by DeGroot LJ, Jameson JL, Philadelphia, W.B. Saunders Co., pp 969–998.eng
dcterms.referencesGoodman WG, Jüppner H, Salusky IB, Sherrard DJ. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int. 2003 Jan;63(1):1-11.eng
dcterms.referencesTanaka M, Komaba H, Itoh K, et al. The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism. NDT Plus. 2008;1(Suppl 3):iii59-iii62.eng
dcterms.referencesZhang Z, Sun S, Quinn SJ, Brown EM, Bai M. The extracellular calcium-sensing receptor dimerizes through multiple types of intermolecular interactions. J Biol Chem. 2001 Feb 16;276(7):5316-22eng
dcterms.referencesKumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol. 2011 Feb;22(2):216-24.eng
dcterms.referencesQuitterer U, Hoffmann M, Freichel M, Lohse MJ. Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J Biol Chem. 2001 Mar 2;276(9):6763-9.eng
dcterms.referencesVilardaga JP, Romero G, Friedman PA, Gardella TJ. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci. 2011 Jan;68(1):1- 13.eng
dcterms.referencesGreenfield EM, Gornik SA, Horowitz MC, Donahue HJ, Shaw SM. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993;8(10):1163-71.eng
dcterms.referencesEfrati E, Arsentiev-Rozenfeld J, Zelikovic I. The human paracellin-1 gene (hPCLN-1): renal epithelial cell-specific expression and regulation. Am J Physiol Renal Physiol 2005;288:F272-F283.eng
dcterms.referencesKulie T, Groff A, Redmer J, Hounshell J, Schrager S. Vitamin D: an evidence-based review. J Am Board Fam Med. 2009 (6):698-706.eng
dcterms.referencesJones G, Byford V, West S, et al. Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs. Anticancer Res2006;26:2.eng
dcterms.referencesHemmingsen C. Regulation of renal calbindin-D28K. Pharmacol Toxicol. 2000;87 Suppl 3:5-30.eng
dcterms.referencesBikle DD. Vitamin D and bone. Curr Osteoporos Rep. 2012;10(2):151-9.eng
dcterms.referencesDavey RA, Findlay DM. Calcitonin: Physiology or Fantasy?. J Bone Miner Res. 2013 May;28(5):973-9.eng
dcterms.referencesShinki T, Ueno Y, DeLuca HF, Suda T. Calcitonin is a major regulator for the expression of renal 25‐hydroxyvitamin D3‐1alpha‐hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci U S A. 1999 Jul;96(14):8253–8eng
dcterms.referencesKawashima H, Torikai S, Kurokawa K. Calcitonin selectively stimulates 25‐hydroxyvitamin D3‐1 alpha‐hydroxylase in proximal straight tubule of rat kidney. Nature. 1981;291(5813):327–9.eng
dcterms.referencesZhang Z, Neff L, Bothwell AL, Baron R, Horne WC. Calcitonin induces dephosphorylation of Pyk2 and phosphorylation of focal adhesion kinase in osteoclasts. Bone. 2002;31(3):359–65.eng
dcterms.referencesMoonga BS, Moss DW, Patchell A, Zaidi M. Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption. J Physiol. 1990;429:29–45.eng
dcterms.referencesMancini L, Moradi‐Bidhendi N, Brandi ML, Perretti M, MacIntyre I. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. Biochem Biophys Res Commun. 2000;279(2):391–7.eng
dcterms.referencesUrruticoechea-Arana A, Martín-Martínez MA, Castañeda S, Piedra CA, González-Juanatey C, Llorca J, Díaz-Gonzalez F, González-Gay MA; CARMA Project Collaborative Group. Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study. Arthritis Res Ther. 2015;17:211.eng
dcterms.referencesBilir B, Tulubas F, Bilir BE, Atile NS, Kara SP, Yildirim T, Gumustas SA, Topcu B, Kaymaz O, Aydin M. The association of vitamin D with inflammatory cytokines in diabetic peripheral neuropathy. J Phys Ther Sci. 2016;28(7):2159-63.eng
dcterms.referencesoergensen C, Gall MA, Schmedes A, Tarnow L, Parving HH, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care. 2010;33(10):2238-43.eng
dcterms.referencesLang CL, Wang MH, Chiang CKK, Lu KC. Vitamin D and the Immune System from the Nephrologist’s Viewpoint. ISRN Endocrinology. 2014:2014105456.eng
dcterms.referencesAggarwal R, Akhthar T, Jain SK. Coronary artery disease and its association with Vitamin D deficiency. J Midlife Health. 2016;7(2):56-60.eng
dcterms.referencesSyal SK, Kapoor A, Bhatia E, Sinha A, Kumar S, Tewari S, Garg N, Goel PK. Vitamin D deficiency, coronary artery disease, and endothelial dysfunction: observations from a coronary angiographic study in Indian patients. J Invasive Cardiol. 2012;24(8):385-9.eng
dcterms.referencesDressler N, Chandra A, Aguirre Dávila L, Spineli LM, Schippert C, von Versen-Höynck F. BMI and season are associated with vitamin D deficiency in women with impaired fertility: a two-centre analysis. Arch Gynecol Obstet. 2016 Apr;293(4):907-14.eng
dcterms.referencesDabrowski FA, Grzechocinska B, Wielgos M. The role of vitamin D in reproductive health--a Trojan Horse or the Golden Fleece? Nutrients. 2015;7(6):4139-53.eng
dcterms.referencesSowell KD, Keen CL, Uriu-Adams JY. Vitamin D and Reproduction: From Gametes to Childhood. Healthcare (Basel). 2015;3(4):1097-120.eng
dcterms.referencesNeupane SP, Lien L, Hilberg T, Bramness JG. Vitamin D deficiency in alcohol-use disorders and its relationship to comorbid major depression: a cross-sectional study of inpatients in Nepal. Drug Alcohol Depend. 2013;133(2):480-5.eng
dcterms.referencesAnglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry. 2013;202:100-7.eng
dcterms.referencesGuo Y, Li Z, Ding R, Li H, Zhang L, Yuan W, Wang Y. Parathyroid hormone induces epithelialto- mesenchymal transition via the Wnt/β-catenin signaling pathway in human renal proximal tubular cells. Int J Clin Exp Pathol. 2014;7(9):5978-87.eng
dcterms.referencesAbdallah Sassine Geara, Mario R. Castellanos, Claude Bassil, Georgia Schuller-Levis, Eunkue Park, Marianne Smith, Michael Goldman, and Suzanne Elsayegh. Effects of Parathyroid Hormone on Immune Function. Clinical and Developmental Immunology. 2010;2010418695.eng
dcterms.referencesPerkovic V, Hewitson TD, Kelynack KJ, Martic M, Tait MG, Becker GJ. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res. 2003;26(1):27-33.eng
dcterms.referencesSchlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone- related peptide. Cardiovasc Res. 1998;37(1):34-41.eng
dcterms.referencesBrown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH, Ruan DT, Williams GH, Adler GK, Vaidya A. Human interventions to characterize novel relationships between the reninangiotensin- aldosterone system and parathyroid hormone. Hypertension. 2014;63(2):273-80.eng
dcterms.referencesJiang B, Morimoto S, Yang J, Niinoabu T, Fukuo K, Ogihara T. Expression of parathyroid hormone/ parathyroid hormone-related protein receptor in vascular endothelial cells. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S142-4.eng
dcterms.referencesRosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrino. 1987;112(3):431-7.eng
dcterms.referencesAtlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 Suppl B):9-20.eng
dcterms.referencesSharma J, Itum DS, Moss L, Chun-Li C, Weber C. Predictors of bone mineral density improvement in patients undergoing parathyroidectomy for primary hyperparathyroidism. World J Surg. 2014;38(6):1268-73.eng
dcterms.referencesBerger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, Adachi JD, Prior JC, Towheed T, Davison KS, Kaiser SM, Brown JP, Goltzman D; the CaMos Research Group. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf). 2014 Jul 25.eng
dcterms.referencesSilverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Liu JM, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580-94.eng
dcterms.referencesAACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005;11(1):49- 54.eng
dcterms.referencesTwigt BA, Scholten A, Valk GD, Rinkes IH, Vriens MR. Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J Rare Dis. 2013;8:50.eng
dcterms.referencesTakami H, Shirahama S, Ikeda Y, Sasaki Y, Wada N, Niimi M, Kameyama K. Familial hyperparathyroidism. Biomed Pharmacother. 2000;54 Suppl 1:21s-24s.eng
dcterms.referencesPepe J, Cipriani C, Pilotto R, De Lucia F, Castro C, Lenge L, Russo S, Guarnieri V, Scillitani A, Carnevale V, D’Erasmo E, Romagnoli E, Minisola S. Sporadic and hereditary primary hyperparathyroidism. J Endocrinol Invest. 201;34(7 Suppl):40-4.eng
dcterms.referencesAlbright F, Reifenstein EC. The parathyroid glands and metabolic bone disease. Baltimore: Williams & Wilkins; 1984. pp. 145–204.eng
dcterms.referencesGhada El-Hajj Fuleihan. Hyperparathyroidism: Time to Reconsider Current Clinical Decision Paradigms?. J Clin Endocrinol Metab. September 2008, 93(9):3302–3304.eng
dcterms.referencesRao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, Mithal A. Role of vitamin D and nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002;17:N75–80.eng
dcterms.referencesKollars J, Zarroug AE, van Heerden J, Lteif A, Stavlo P, Suarez L, Moir C, Ishitani M, Rodeberg D. Primary hyperparathyroidism in pediatric patients. Pediatrics. 2005;115(4):974-80.eng
dcterms.referencesBroulík P, Adámek S, Libánský P, Kubinyi J. Changes in the Pattern of Primary Hyperparathyroidism in Czech Republic. Prague Med Rep. 2015;116(2):112-21.eng
dcterms.referencesSambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, Schwarz J, Seibel MJ. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab. 2004; 89: 5477–5481.eng
dcterms.referencesHagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119(21):2765-71.eng
dcterms.referencesPilz S1, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31(13):1591-8.eng
dcterms.referencesBro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis. 1997;30(5):606-20.eng
dcterms.referencesPirro M, Manfredelli MR, Helou RS, Scarponi AM, Schillaci G, Bagaglia F, Melis F, Mannarino E. Association of parathyroid hormone and 25-OH-vitamin D levels with arterial stiffness in postmenopausal women with vitamin D insufficiency. J Atheroscler Thromb. 2012;19:924–931.eng
dcterms.referencesRashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol. 2007; 292: F1215–F1218.eng
dcterms.referencesAmann K, Tornig J, Flechtenmacher C, Nabokov A, Mall G, Ritz E. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant. 1995; 10: 2043–2048.eng
dcterms.referencesRosenthal FD, Roy S. Hypertension and Hyperparathyroidism. Br Med J. 1972; 4(5837): 396– 397.eng
dcterms.referencesEufrazino C, Veras A, Bandeira F. Epidemiology of Primary Hyperparathyroidism and its Nonclassical Manifestations in the City of Recife, Brazil. Clin Med Insights Endocrinol Diabetes. 2013;6:69-74.eng
dcterms.referencesMadhavan T, Frame B, Block MA. Influence of surgical correction of primary hyperparathyroidism on associated hypertension. Arch Surg. 1970;100(2):212-4.eng
dcterms.referencesFeldstein CA, Akopian M, Pietrobelli D, Olivieri A, Garrido D. Long-term effects of parathyroidectomy on hypertension prevalence and circadian blood pressure profile in primary hyperparathyroidism. Clin Exp Hypertens. 2010;32(3):154-8.eng
dcterms.referencesLuigi P, Chiara FM, Laura Z, Cristiano M, Giuseppina C, Luciano C, Giuseppe P, Sabrina C, Susanna S, Antonio C, Giuseppe C, Giorgio de T, Claudio L. Arterial Hypertension, Metabolic Syndrome and Subclinical Cardiovascular Organ Damage in Patients with Asymptomatic Primary Hyperparathyroidism before and after Parathyroidectomy: Preliminary Results. Int J Endocrinol. 2012;2012:408295.eng
dcterms.referencesMazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab. 2001;280(2):E209-13.eng
dcterms.referencesChowdhury SD, Gray JG. Renal function and hypertension in primary hyperparathyroidism. Br J Surg. 1973;60(1):53-6.eng
dcterms.referencesHELLSTROM J, BIRKE G, EDVALL CA. Hypertension in hyperparathyroidism. Br J Urol. 1958 Mar;30(1):13–24eng
dcterms.referencesMulvany MJ. Small artery remodelling in hypertension. Basic Clin Pharmacol Toxicol. 2012;110(1):49-55.eng
dcterms.referencesUreña P, Kong XF, Abou-Samra AB, Jüppner H, Kronenberg HM, Potts JT Jr, Segre GV. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology. 1993;133(2):617-23.eng
dcterms.referencesKitazawa S, Fukase M, Kitazawa R, Takenaka A, Gotoh A, Fujita T, Maeda S. Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer. 1991;67(4):984-9.eng
dcterms.referencesLupp A, Klenk C, Röcken C, Evert M, Mawrin C, Schulz S. Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. Eur J Endocrinol. 2010;162(5):979-86.eng
dcterms.referencesMarotta SF. The role of parathyroid hormone and thyrocalcitonin in altering plasma calcium levels and adrenocortical secretory rates. Horm Metab Res. 1971;3(5):344-8.eng
dcterms.referencesLasco A, Catalano A, Morabito N, Gaudio A, Basile G, Trifiletti A, Atteritano M. Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis. Osteoporos Int. 2011;22(1):299-303.eng
dcterms.referencesBetancourt-Calle S, Calle RA, Isales CM, White S, Rasmussen H, Bollag WB. Differential effects of agonists of aldosterone secretion on steroidogenic acute regulatory phosphorylation. Mol Cell Endocrinol. 2001;173(1-2):87-94.eng
dcterms.referencesHattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350(2):151-62.eng
dcterms.referencesMidzak A, Rone M, Aghazadeh Y, Culty M, Papadopoulos V. Mitochondrial protein import and the genesis of steroidogenic mitochondria. Mol Cell Endocrinol. 2011;336(1-2):70-9.eng
dcterms.referencesMiller WL. Steroid hormone synthesis in mitochondria. Mol Cell Endocrinol. 2013;379(1-2):62- 73.eng
dcterms.referencesPython CP, Laban OP, Rossier MF, Vallotton MB, Capponi AM. The site of action of Ca2+ in the activation of steroidogenesis: studies in Ca(2+)-clamped bovine adrenal zona-glomerulosa cells. Biochem J. 1995;305 ( Pt 2):569-76.eng
dcterms.referencesCherradi N, Rossier MF, Vallotton MB, Capponi AM. Calcium stimulates intramitochondrial cholesterol transfer in bovine adrenal glomerulosa cells. J Biol Chem. 1996;271(42):25971-5.eng
dcterms.referencesHiguchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond). 2007;112(8):417-28.eng
dcterms.referencesCapponi AM, Lew PD, Jornot L, Vallotton MB. Correlation between cytosolic free Ca2+ and aldosterone production in bovine adrenal glomerulosa cells. Evidence for a difference in the mode of action of angiotensin II and potassium. J Biol Chem. 1984;259(14):8863-9.eng
dcterms.referencesIsales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. 1991;129(1):489-95.eng
dcterms.referencesOlgaard K, Lewin E, Bro S, Daugaard H, Egfjord M, Pless V. Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone. Miner Electrolyte Metab. 1994;20(5):309-14.eng
dcterms.referencesSpät A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84(2):489-539.eng
dcterms.referencesRossier MF, Ertel EA, Vallotton MB, Capponi AM. Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells. J Pharmacol Exp Ther. 1998;287(3):824-31.eng
dcterms.referencesYao J, Davies LA, Howard JD, Adney SK, Welsby PJ, Howell N, Carey RM, Colbran RJ, Barrett PQ. Molecular basis for the modulation of native T-type Ca2+ channels in vivo by Ca2+/calmodulindependent protein kinase II. J Clin Invest. 2006;116(9):2403-12.eng
dcterms.referencesLotshaw DP. Role of membrane depolarization and T-type Ca2+channels in angiotensin II and K+ stimulated aldosterone secretion. Mol Cell Endocrinol. 2001;175: 157–171, 2001.eng
dcterms.referencesBalla T, Várnai P, Holló Z, Spät A. Effects of high potassium concentration and dihydropyridine Ca2(+)-channel agonists on cytoplasmic Ca2+ and aldosterone production in rat adrenal glomerulosa cells. Endocrinology. 1990;127(2):815-22.eng
dcterms.referencesEly JA, Ambroz C, Baukal AJ, Christensen SB, Balla T, Catt KJ. Relationship between agonistand thapsigargin-sensitive calcium pools in adrenal glomerulosa cells. Thapsigargin-induced Ca2+ mobilization and entry. J Biol Chem. 1991;266(28):18635-41.eng
dcterms.referencesHaksar A, Péron FG. The role of calcium in the steroidogenic response of rat adrenal cells to adrenocorticotropic hormone. Biochim Biophys Acta. 1973;313(2):363-71.eng
dcterms.referencesHyatt PJ, Tait JF, Tait SAS. The mechanism of the effect of K+ on the steroidogenesis of rat zona glomerulosa cells of the adrenal cortex: role of cyclic AMP. Proc R Soc Lond B Biol Sci. 1986;227: 21–42.eng
dcterms.referencesTait JF, Tait SA. Role of AMPc in the effects of K+ on the steroidogenesis of zona glomerulosa cells. Clin Exp Pharmacol Physiol. 1999;26(12):947-55.eng
dcterms.referencesAntoni FA. Calcium regulation of adenylyl cyclase relevance for endocrine control. Trends Endocrinol Metab. 1997;8(1):7-14.eng
dcterms.referencesCôté M, Guillon G, Payet MD, Gallo-Payet N. Expression and regulation of adenylyl cyclase isoforms in the human adrenal gland. J Clin Endocrinol Metab. 2001;86(9):4495-503.eng
dcterms.referencesConnell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186(1):1-20.eng
dcterms.referencesNogueira EF, Rainey W. Regulation of Aldosterone Synthase by Activator Transcription Factor/ cAMP Response Element-Binding Protein Family Members. Endocrinology. 2010; 151(3): 1060–1070.eng
dcterms.referencesNogueira EF, Xing Y, Morris CA, Rainey NOSOTROS. Role of angiotensin II-induced rapid response genes in the regulation of enzymes needed for aldosterone synthesis. J Mol Endocrinol 2009; 42 (4) :319-30.eng
dcterms.referencesPezzi V, Clyne CD, Ando S, Mathis JM, Rainey WE. Ca(2+)-regulated expression of aldosterone synthase is mediated by calmodulin and calmodulin-dependent protein kinases. Endocrinology. 1997;138(2):835-8.eng
dcterms.referencesIkeda K, Isaka T, Fujioka K, Manome Y, Tojo K. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467.eng
dcterms.referencesSirianni R, Nogueira E, Bassett MH, Carr BR, Suzuki T, Pezzi V, Andò S, Rainey WE. The AP-1 family member FOS blocks transcriptional activity of the nuclear receptor steroidogenic factor 1. J Cell Sci. 2010 Nov 15;123(Pt 22):3956-65.eng
dcterms.referencesHoeflich A, Bielohuby M. Mechanisms of adrenal gland growth: signal integration by extracellular signal regulated kinases1/2. J Mol Endocrinol. 2009;42(3):191-203.eng
dcterms.referencesMiller WL, Auchus RJ.The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81-151.eng
dcterms.referencesSchillaci G, Pucci G, Pirro M, Monacelli M, Scarponi AM, Manfredelli MR, Rondelli F, Avenia N, Mannarino E. Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis. 2011;218(1):96-101.eng
dcterms.referencesIwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R, Sacco RL, Homma S, Silverberg SJ. Aortic Valve Calcification in Mild Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2012; 97(1): 132–137.eng
dcterms.referencesBrown J, de Boer IH, Robinson-Cohen C, Siscovick DS, Kestenbaum B, Allison M, Vaidya A. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100(2):490-9.eng
dcterms.referencesSaussine C, Judes C, Massfelder T, Musso MJ, Simeoni U, Hannedouche T, Helwig JJ. Stimulatory action of parathyroid hormone on renin secretion in vitro: a study using isolated rat kidney, isolated rabbit glomeruli and superfused dispersed rat juxtaglomerular cells. Clin Sci (Lond). 1993;84(1):11-9.eng
dcterms.referencesFriis UG, Madsen K, Stubbe J, Hansen PB, Svenningsen P, Bie P, Skøtt O, Jensen BL. Regulation of renin secretion by renal juxtaglomerular cells. Pflugers Arch. 2013;465(1):25-37.eng
dcterms.referencesPedraza-Chaverri J, Ibarra-Rubio ME, Cruz C, Tapi E. [Intracellular messengers in the regulation of renin secretion]. [Article in Spanish]. Rev Invest Clin. 1989 Apr-Jun;41(2):165-75.eng
dcterms.referencesSchweda F, Friis U, Wagner C, Skott O, Kurtz A. Renin release. Physiology (Bethesda). 2007;22:310-9.eng
dcterms.referencesBeierwaltes WH. The role of calcium in the regulation of renin secretion. Am J Physiol Renal Physiol. 2010;298(1):F1-F11.eng
dcterms.referencesOrtiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. Decreased intracellular calcium stimulates renin release via calcium-inhibitable adenylyl cyclase. Hypertension. 2007;49(1):162-9.eng
dcterms.referencesOrtiz-Capisano MC, Reddy M, Mendez M, Garvin JL, Beierwaltes WH. Juxtaglomerular cell CaSR stimulation decreases renin release via activation of the PLC/IP(3) pathway and the ryanodine receptor. Am J Physiol Renal Physiol. 2013;304(3):F248-56.eng
dcterms.referencesOrtiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. Adenylyl cyclase isoform v mediates renin release from juxtaglomerular cells. Hypertension. 2007;49(3):618-24.eng
dcterms.referencesExpression and function of the calcium-sensing receptor in juxtaglomerular cells. Ortiz-Capisano MC, Ortiz PA, Garvin JL, Harding P, Beierwaltes WH. Hypertension. 2007;50(4):737-43.eng
dcterms.referencesAtchison DK, Harding P, Beierwaltes WH. Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension. 2011;58(4):604-10.eng
dcterms.referencesBukoski RD, Ishibashi K, Bian K. Vascular actions of the calcium-regulating hormones. Semin Nephrol. 1995;15(6):536-49.eng
dcterms.referencesWang R, Karpinski E, Pang PK. Parathyroid hormone selectively inhibits L-type calcium channels in single vascular smooth muscle cells of the rat. J Physiol. 1991 Sep; 441: 325–346.eng
dcterms.referencesHelwig JJ, Musso MJ, Judes C, Nickols GA. Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology. 1991;129(3):1233-42.eng
dcterms.referencesYoung WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-18.eng
dcterms.referencesRossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-300.eng
dcterms.referencesZennaro MC, Boulkroun S, Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism. J Endocrinol. 2015;224(2):R63-77.eng
dcterms.referencesYoung WF Jr. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord. 2007;8(4):309-20.eng
dcterms.referencesSavard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331-6.eng
dcterms.referencesRossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, Calò LA, Frigo AC, Fassina A, Pessina AC. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension. 2012;60(2):431-6.eng
dcterms.referencesResnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78(3):385-90.eng
dcterms.referencesResnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105(5):649-54.eng
dcterms.referencesPilz S, Tomaschitz A, März W, Cavalier E, Ritz E. Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int. 2010 Oct;87(4):373-4.eng
dcterms.referencesRossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8(9):884-93.eng
dcterms.referencesKabadi UM. Renal calculi in primary hyperaldosteronism. J Postgrad Med 1995;41:17–18.eng
dcterms.referencesShey J, Cameron MA, Sakhaee K, Moe OW. Recurrent calcium nephrolithiasis associated with primary aldosteronism. Am J Kidney Dis. 2004;44(1):e7-12.eng
dcterms.referencesYasuda K, Sasaki K, Yamato M, Rakugi H, Isaka Y, Hayashi T. A case of nephrocalcinosis associated with primary aldosteronism. Intern Med. 2012;51(6):625-7eng
dcterms.referencesPilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, März W, Pieber TR, Tomaschitz A. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012;97(1):E75-9.eng
dcterms.referencesLaguardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006;332(3):112-8.eng
dcterms.referencesSun Y, Ahokas RA, Bhattacharya SK, Gerling IC, Carbone LD, Weber KT. Oxidative stress in aldosteronism. Cardiovascular Research. 2006;71(2):300-309.eng
dcterms.referencesManiero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension. 2011;58(3):341-6.eng
dcterms.referencesLeopold JA. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation. 2011;124(18):e466-8.eng
dcterms.referencesCheng SP, Liu CL, Liu TP, Hsu YC, Lee JJ. Association between Parathyroid Hormone Levels and Inflammatory Markers among US Adults. Mediators of Inflammation. 2014;2014709024.eng
dcterms.referencesOgard CG, Engelmann MD, Kistorp C, Nielsen SL, Vestergaard H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related toatherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63(5):493-8.eng
dcterms.referencesEmam AA, Mousa SG, Ahmed KY, Al-Azab AA. Inflammatory biomarkers in patients with asymptomatic primary hyperparathyroidism. Med Princ Pract. 2012;21(3):249-53.eng
dcterms.referencesKaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.eng
dcterms.referencesChang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol. 2009;307(1-2):77-82.eng
dcterms.referencesChristensen MH, Dankel SN, Nordbø Y, Varhaug JE, Almås B, Lien EA, Mellgren G. Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. PLoS One. 2011;6(6):e20481.eng
dcterms.referencesMittendorfer B. Origins of metabolic complications in obesity: adipose tissue and free fatty acid trafficking. Curr Opin Clin Nutr Metab Care. 2011;14(6):535-41.eng
dcterms.referencesVirdis A, Santini F, Colucci R, Duranti E, Salvetti G, Rugani I, Segnani C, Anselmino M, Bernardini N, Blandizzi C, Salvetti A, Pinchera A, Taddei S. Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol. 2011;58(3):238-47.eng
dcterms.referencesVirdis A, Duranti E, Rossi C, Dell’Agnello U, Santini E, Anselmino M, Chiarugi M, Taddei S, Solini A. Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue. Eur Heart J. 2015;36(13):784- 94.eng
dcterms.referencesFarb MG, Ganley-Leal L, Mott M, Liang Y, Ercan B, Widlansky ME, Bigornia SJ, Fiscale AJ, Apovian CM, Carmine B, Hess DT, Vita JA, Gokce N. Arteriolar function in visceral adipose tissue is impaired in human obesity. Arterioscler Thromb Vasc Biol. 2012;32(2):467-73.eng
dcterms.referencesHafner F, Kieninger A, Meinitzer A, Gary T, Froehlich H, Haas E, Hackl G, Eller P, Brodmann M, Seinost G. Endothelial dysfunction and brachial intima-media thickness: long term cardiovascular risk with claudication related to peripheral arterial disease: a prospective analysis. PLoS One. 2014;9(4):e93357.eng
dcterms.referencesEkmekci A, Abaci N, Colak Ozbey N, Agayev A, Aksakal N, Oflaz H, Erginel-Unaltuna N, Erbil Y. Endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism. J Endocrinol Invest. 2009;32(7):611-6.eng
dcterms.referencesKosch M, Hausberg M, Vormbrock K, Kisters K, Gabriels G, Rahn KH, Barenbrock M. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res. 2000;47(4):813-8.eng
dcterms.referencesKosch M, Hausberg M, Vormbrock K, Kisters K, Rahn KH, Barenbrock M. Studies on flow-mediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism. Am J Hypertens. 2000;13(7):759-64.eng
dcterms.referencesTuna MM, Doğan BA, Arduç A, Imga NN, Tütüncü Y, Berker D, Güler S. Impaired endothelial function in patients with mild primary hyperparathyroidism improves after parathyroidectomy. Clin Endocrinol (Oxf). 2015;83(6):951-6.eng
dcterms.referencesYilmaz BA, Toruner B, Akyel A, Ercin U, Değertekin CK, Lyidir OT, Tavil Y, Bilgihan A, Arslan M. ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM. Acta Endocrinologica (Buc). 2015;XI(4):482-488.eng
dcterms.referencesChhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111(7):871-8.eng
dcterms.referencesBhattacharya SK, Gandhi MS, Kamalov G, Ahokas RA, Sun Y, Gerling IC, Weber KT. Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism. Curr Hypertens Rep. 2009;11(6):412-20.eng
dcterms.referencesVidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290(1):H286-94.eng
dcterms.referencesYusuf J, Khan MU, Cheema Y, Bhattacharya SK, Weber KT. Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones. Prog Cardiovasc Dis. 2012;55(1):77-86.eng
dcterms.referencesBogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest. 1981; 67(4):1215–1227.eng
dcterms.referencesBogin E, Levi J, Harary I, Massry SG. Effects of parathyroid hormone on oxidative phosphorylation of heart mitochondria. Miner Electrolyte Metab. 1982;7(3):151-6.eng
dcterms.referencesBaczynski R, Massry SG, Kohan R, Magott M, Saglikes Y, Brautbar N. Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int. 1985;27(5):718-25.eng
dcterms.referencesShaheen M, Cheema Y, Shahbaz AU, Bhattacharya SK, Weber KT. Intracellular calcium overloading and oxidative stress in cardiomyocyte necrosis via a mitochondriocentric signal-transducer- effector pathway. Exp Clin Cardiol. 2011;16(4):109-15.eng
dcterms.referencesRutledge MR, Farah V, Adeboye AA, Seawell MR, Bhattacharya SK, Weber KT. Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther. 2013;27(2):161-70.eng
dcterms.referencesGallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13(1):114-9.eng
dcterms.referencesSun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161(5):1773-81.eng
dcterms.referencesThomas M, Vidal A, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. Am J Physiol Heart Circ Physiol. 2007;293(4):H2361-6.eng
dcterms.referencesDe Marchi E, Baldassari F, Bononi A, Wieckowski MR, Pinton P. Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and protein kinase C. Oxid Med Cell Longev. 2013;2013:564961.eng
dcterms.referencesPerrotta I, Aquila S. The role of oxidative stress and autophagy in atherosclerosis. Oxid Med Cell Longev. 2015;2015:130315.eng
dcterms.referencesTaylor EN, Curhan GC, Forman JP. Parathyroid hormone and the risk of incident hypertension. J Hypertens. 2008;26(7):1390-4.eng
dcterms.referencesvan Ballegooijen AJ, Kestenbaum B, Sachs MC, de Boer IH, Siscovick DS, Hoofnagle AN, Ix JH, Visser M, Brouwer IA. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63(12):1214-22.eng
dcterms.referencesYagi S, Aihara K, Kondo T, Endo I, Hotchi J, Ise T, Iwase T, Akaike M, Matsumoto T, Sata M. High serum parathyroid hormone and calcium are risk factors for hypertension in Japanese patients. Endocr J. 2014;61(7):727-33.eng
dcterms.referencesLafferty FW. Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests. Arch Intern Med. 1981;141(13):1761-6.eng
dcterms.referencesHeyliger A, Tangpricha V, Weber C, Sharma J. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery. 2009;146(6):1042-7.eng
dcterms.referencesBroulik PD, Brouliková A, Adámek S, Libanský P, Tvrdoň J, Broulikova K, Kubinyi J. Improvement of hypertension after parathyroidectomy of patients suffering from primary hyperparathyroidism. Int J Endocrinol. 2011;2011:309068.eng
dcterms.referencesGennari C, Nami R, Gonnelli S. Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems. Miner Electrolyte Metab. 1995;21(1- 3):77-81.eng
dcterms.referencesKovács L, Góth MI, Szabolcs I, Dohán O, Ferencz A, Szilágyi G. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol. 1998 May;138(5):543-7.eng
dcterms.referencesChen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, Liang J, Li L, Lin W, Lin L, Shi L, Cai L, Wen J. Is Normocalcemic Primary Hyperparathyroidism Harmful or Harmless? J Clin Endocrinol Metab. 2015;100(6):2420-4.eng
dcterms.referencesVerheyen N, Fahrleitner-Pammer A, Pieske B, Meinitzer A, Belyavskiy E, Wetzel J, Gaksch M, Grübler MR, Catena C, Sechi LA, Van Ballegooijen AJ, Brandenburg VM, Scharnagl H, Perl S, Brussee H, März W, Pilz S, Tomaschitz A. Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial. J Hypertens. 2016;34(9):1778- 86.eng
dcterms.referencesTomaschitz A, Verheyen N, Meinitzer A, Pieske B, Belyavskiy E, Brussee H, Haas J, März W, Pieske-Kraigher E, Verheyen S, Ofner-Ziegenfuss L, Hartaigh BÓ, Schwetz V, Aberer F, Grübler M, Lang F, Alesutan I, Voelkl J, Gaksch M, Horina JH, Dimai HP, Rus-Machan J, Stiegler C, Ritz E, Fahrleitner-Pammer A, Pilz S. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebocontrolled trial. J Hypertens. 2016;34(7):1347-56.eng
dcterms.referencesNilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism-effects of parathyroidectomy. Surgery. 2000;128(6):895- 902.eng
dcterms.referencesOsto E, Fallo F, Pelizzo MR, Maddalozzo A, Sorgato N, Corbetti F, Montisci R, Famoso G, Bellu R, Lüscher TF, Iliceto S, Tona F. Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation. 2012;126(9):1031-9.eng
dcterms.referencesMcMahon DJ, Carrelli A, Palmeri N, Zhang C, DiTullio M, Silverberg SJ, Walker MD. Effect of Parathyroidectomy Upon Left Ventricular Mass in Primary Hyperparathyroidism: A Meta- Analysis. J Clin Endocrinol Metab. 2015;100(12):4399-407eng
dcterms.referencesSchiffl H, Lang SM. Hypertension secondary to PHPT: cause or coincidence? Int J Endocrinol 2011;2011:974647.eng
dcterms.referencesAndersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease--a review. Eur Heart J. 2004;25(20):1776-87.eng
dcterms.referencesWalker MD, Rundek T, Homma S, DiTullio M, Iwata S, Lee JA, Choi J, Liu R, Zhang C, McMahon DJ, Sacco RL, Silverberg SJ. Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur J Endocrinol. 2012;167(2):277-85.eng
dcterms.referencesYener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I, Dogan Cakir S, Altuntas Y. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J. 2016;63(2):111-8.eng
dcterms.referencesBjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology. 2009;55(6):601-6.eng
dcterms.referencesCawthon PM, Parimi N, Barrett-Connor E, Laughlin GA, Ensrud KE, Hoffman AR, Shikany JM, Cauley JA, Lane NE, Bauer DC, Orwoll ES, Cummings SR; Osteoporotic Fractures in Men (MrOS) Research Group. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. J Clin Endocrinol Metab. 2010;95(10):4625-34eng
dcterms.referencesGrandi NC, Breitling LP, Hahmann H, Wüsten B, März W, Rothenbacher D, Brenner H. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart. 2011;97(15):1215-21.eng
dcterms.referencesvan Ballegooijen AJ, Reinders I, Visser M, Dekker JM, Nijpels G, Stehouwer CD, Pilz S, Brouwer IA. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab. 2013;98(4):E638-45.eng
dcterms.referencesTomaschitz A, Pilz S, Rus-Machan J, Meinitzer A, Brandenburg VM, Scharnagl H, Kapl M, Grammer T, Ritz E, Horina JH, Kleber ME, Pieske B1, Kraigher-Krainer E, Hartaigh BÓ, Toplak H, van Ballegooijen AJ, Amrein K, Fahrleitner-Pammer A, März W. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. Int J Cardiol. 2015;184:710-6.eng
dcterms.referencesvan Ballegooijen AJ, Reinders I, Visser M, Brouwer IA. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J. 2013;165(5):655-64, 664.e1-5.eng
dcterms.referencesYang B, Lu C, Wu Q, Zhang J, Zhao H, Cao Y. Parathyroid hormone, cardiovascular and all-cause mortality: A meta-analysis. Clin Chim Acta. 2016;455:154-60.eng
dcterms.referencesKamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study. Eur J Cardiovasc Prev Rehabil. 2004;11(1):69-74.eng
dcterms.referencesJassal SK, Chonchol M, von Mühlen D, Smits G, Barrett-Connor E. Vitamin d, parathyroid hormone, and cardiovascular mortality in older adults: the Rancho Bernardo study. Am J Med. 2010;123(12):1114-20.eng
dcterms.referencesTaylor EN, Rimm EB, Stampfer MJ, Curhan GC. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011;161(5):956-62.eng
dcterms.referencesSzulc P, Claustrat B, Delmas PD. Serum concentrations of 17beta-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men--the MINOS study. Clin Endocrinol (Oxf). 2009;71(4):594-602.eng
dcterms.referencesLee DM, Vanderschueren D, Boonen S, O’Neill TW, Pendleton N, Pye SR, Ravindrarajah R, Gielen E, Claessens F, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Wu FC; European Male Ageing Study Group. Association of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone with mortality among middle-aged and older European men. Age Ageing. 2014;43(4):528-35eng
dcterms.referencesPalmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119-27.eng
dcterms.referencesNatoli JL, Boer R, Nathanson BH, Miller RM, Chiroli S, Goodman WG, Belozeroff V. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol. 2013;14:88.eng
dcterms.referencesKestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, Jenny NS, Siscovick DS. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58(14):1433-41.eng
dcterms.referencesHagström E, Ingelsson E, Sundström J, Hellman P, Larsson TE, Berglund L, Melhus H, Held C, Michaëlsson K, Lind L, Arnlöv J. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12(11):1186-92.eng
dcterms.referencesSchierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JE. Parathyroid hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13(6):626-32.eng
dcterms.referencesEigelberger MS, Cheah WK, Ituarte PH, Streja L, Duh QY, Clark OH. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg. 2004;239(4):528-35.eng
dcterms.referencesPalazzo FF, Delbridge LW. Minimal-access/minimally invasive parathyroidectomy for primary hyperparathyroidism. Surg Clin North Am. 2004;84(3):717-34.eng
dcterms.referencesPallan S, Khan A. Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician. 2011;57(2):184-9.eng
dcterms.referencesTomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N, Gaksch M, Grübler M, Fahrleitner-Pammer A, Mrak P, Toplak H, Kraigher-Krainer E, März W, Pilz S. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63(1):20-31.eng
dcterms.referencesTomaschitz A, Ritz E, Pieske B, Fahrleitner-Pammer A, Kienreich K, Horina JH, Drechsler C, März W, Ofner M, Pieber TR, Pilz S. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res. 2012;94(1):10-9.eng

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca